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693Abstracts
thermore, FC and HC differ in valuation of both volume
and price. Apart from the differences between FC and
HC, neither method takes account of disablement. Many
patients were disabled at the start of the study, and in the
majority of cases, disablement was due to BPD. FC does
not take these costs into account. Although HC is poten-
tially able to value the costs of disablement, this is cur-
rently not the practice in RCTs. However, production
losses associated with disablement are considerable. In
addition, neither FC nor HC provides an answer to the
question what calculations to perform when a person
recovers from disablement and resumes work.
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OBJECTIVES: Frequency of adverse events -AEs- related
with antipsychotics usage is high. Along with clinical
implications, economic impact might be important. A
pharmacoeconomic model has been developed to ascer-
tain the economic impact of patients experiencing these
AEs. The purpose of this study was to model the eco-
nomic consequences of AEs related with current antipsy-
chotics in Spain. METHODS: A cost-effectiveness model
was developed using a Markov modeling approach sim-
ulating treatment of a cohort of schizophrenics for 12
months, initiating treatment with one of four antipsy-
chotic drugs; haloperidol, risperidone, olanzapine and
ziprasidone. The model assumes equivalent efﬁcacy
among the antipsychotics. Conditional probabilities of
developing any of four adverse events was calculated.
Treatment was modiﬁed (decrease dose, switch medica-
tion) according to incidence of AEs and physician judg-
ments, obtained from a local cross-sectional study and
clinical trials previously published. The analysis was con-
ducted in year 2002 from a 3rd party payer perspective
(only direct medical cost are computed). Results are
shown as annual cost per month with psychotic symp-
toms controlled. Univariate sensitivity analysis was per-
formed. RESULTS: The therapeutic strategy starting with
Ziprasidone showed the most favorable cost-effectiveness
ratio, being the dominant option (showing the lower costs
and the greater number of months with symptoms con-
trolled), versus the other options considered. The annual
cost per patient per month with symptoms controlled was
€1.035 with that of ziprasidone, versus €1.084, €1.087,
and €1.090 with haloperidol, risperidone and olanzapine,
respectively. Results are robust to one-way sensitivity
analysis. CONCLUSIONS: Adverse events related with
the usage of antipsychotic drugs produce a considerable
economic impact. Availability of drugs with similar effec-
tiveness but better tolerability than existing agents,
should positively impact on clinic aspects of schizophre-
nia and health care budgets as well.
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OBJECTIVE: Although affective psychoses are usually
associated with adults, it has been reported that at any
given point in time approximately 5% of children and
adolescents in the U.S. general population suffer from
depression. This study sought to identify adolescents
(10–19 years) requiring acute hospital management in
1998 for affective psychoses, their readmissions for these
problems over a 3-year period and the resulting costs.
METHODS: The index admission was identiﬁed in the
1998 Massachusetts all payer hospital database using
ICD-9 diagnosis codes. Suicide attempts were identiﬁed
by E codes. Readmissions were tracked over three years
(1998–2000) by means of a unique patient identiﬁer. All
accommodations, ancillaries and physician services were
included in the cost estimates, which were adjusted for
medical inﬂation, national values, cost-to-charge ratios,
and reported in 2003 US$. RESULTS: A cohort of 890
patients was identiﬁed with 26% coded as bipolar; 12%
admitted due to intentional self-harm. Mean age was 16.4
years (22% = 10–14 years, 78% = 15–19 years); 45%
were male. Index admission mean length of stay was 8.5
days (range: 1–106); 68% spent time in a psychiatric unit.
Mean cost per stay was $7,239 (range: $491–$107,747).
All survived the hospital stay. At discharge, 5% were
transferred to mental health facilities (MHF). Subsequent
to index admission, 25% were readmitted at least once
(mean 1.5, range: 1–11) within 3 years for affective psy-
choses or self-harm and all survived to discharge. The
cumulative 3-year hospital cost for study-relevant admis-
sions for the cohort was estimated at $9.1 million. CON-
CLUSIONS: One quarter of adolescents with affective
psychoses who require acute hospital management can 
be expected to incur additional disorder-related hospital
costs within three years. The estimates, albeit conserva-
tive, as outpatient therapy and MHF care were not
included, illustrate the economic consequences of these
disorders for this age group.
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